Zacks Research Has Negative Outlook for Glaukos Q2 Earnings

Glaukos Corporation (NYSE:GKOS) – Equities research analysts at Zacks Research dropped their Q2 2027 earnings per share (EPS) estimates for shares of Glaukos in a research note issued on Wednesday, August 19th. Zacks Research analyst Team now anticipates that the medical instruments supplier will post earnings per share of $0.06 for the quarter, down from their previous estimate of $0.07. The consensus estimate for Glaukos’ current full-year earnings is ($0.35) per share. Zacks Research also issued estimates for Glaukos’ Q3 2027 earnings at $0.10 EPS, Q4 2027 earnings at $0.33 EPS, FY2027 earnings at $0.45 EPS, Q1 2028 earnings at $0.18 EPS, Q2 2028 earnings at $0.37 EPS and FY2028 earnings at $1.70 EPS.

Glaukos (NYSE:GKOS) last released its quarterly earnings results on Wednesday, July 29th. The medical instruments supplier reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.07. The business had revenue of $185.61 million during the quarter, compared to analysts’ expectations of $150.93 million. Glaukos had a negative return on equity of 6.37% and a negative net margin of 30.68%.The company’s quarterly revenue was up 49.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.24) earnings per share.

Several other research analysts have also recently issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Glaukos in a report on Friday, July 17th. JPMorgan Chase & Co. lifted their price objective on Glaukos from $120.00 to $140.00 and gave the company an “overweight” rating in a report on Thursday, April 30th. UBS Group initiated coverage on Glaukos in a research report on Tuesday, July 28th. They set a “neutral” rating and a $150.00 target price on the stock. Wells Fargo & Company increased their target price on Glaukos from $138.00 to $178.00 and gave the stock an “overweight” rating in a research note on Thursday, July 30th. Finally, Needham & Company LLC raised their price target on Glaukos from $150.00 to $201.00 and gave the company a “buy” rating in a report on Thursday, July 30th. Twelve research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $177.33.

Glaukos Stock Up 3.0%

GKOS stock opened at $189.72 on Thursday. Glaukos has a one year low of $73.16 and a one year high of $190.06. The stock has a market capitalization of $11.19 billion, a PE ratio of -58.38 and a beta of 0.78. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.46 and a current ratio of 5.04. The company has a fifty day moving average of $154.98 and a 200-day moving average of $130.78.

Insider Activity at Glaukos

In related news, CFO Alex R. Thurman sold 20,000 shares of the business’s stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $180.13, for a total transaction of $3,602,600.00. Following the sale, the chief financial officer owned 43,906 shares of the company’s stock, valued at approximately $7,908,787.78. The trade was a 31.30% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Joseph E. Gilliam sold 60,000 shares of the company’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $179.74, for a total transaction of $10,784,400.00. Following the transaction, the chief operating officer owned 72,588 shares in the company, valued at $13,046,967.12. The trade was a 45.25% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 110,525 shares of company stock worth $19,125,006 over the last 90 days. Company insiders own 5.90% of the company’s stock.

Institutional Investors Weigh In On Glaukos

A number of institutional investors and hedge funds have recently modified their holdings of the company. First Horizon Corp raised its holdings in Glaukos by 1,715.4% during the fourth quarter. First Horizon Corp now owns 236 shares of the medical instruments supplier’s stock worth $27,000 after purchasing an additional 223 shares during the last quarter. Allworth Financial LP acquired a new stake in Glaukos in the second quarter valued at $28,000. Los Angeles Capital Management LLC acquired a new stake in Glaukos in the fourth quarter valued at $28,000. Larson Financial Group LLC grew its holdings in Glaukos by 62.0% in the fourth quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier’s stock valued at $39,000 after purchasing an additional 132 shares during the last quarter. Finally, Parallel Advisors LLC increased its position in shares of Glaukos by 159.2% in the first quarter. Parallel Advisors LLC now owns 368 shares of the medical instruments supplier’s stock valued at $40,000 after buying an additional 226 shares in the last quarter. Institutional investors and hedge funds own 99.04% of the company’s stock.

Glaukos News Summary

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: Zacks Research raised multiple long-term EPS forecasts. Estimates increased for FY2027 EPS to $0.45 from $0.38, FY2028 EPS to $1.70 from $1.56, Q4 2027 EPS to $0.33 from $0.30, Q1 2028 EPS to $0.18 from $0.16, and Q2 2028 EPS to $0.37 from $0.32. The revisions suggest stronger expected profitability as Glaukos scales its business. Zacks Research article
• Positive Sentiment: Growth catalysts remain intact. Zacks highlighted Glaukos’ iDose TR and Epioxa products, margin-expansion potential, and broad development pipeline as reasons to retain the stock. These factors support the long-term growth narrative behind GKOS.
• Neutral Sentiment: Management will participate in the Wells Fargo Healthcare Conference on September 9, 2026. The event could provide updates on product launches, clinical programs, and financial goals, although no new operating information was announced. Glaukos Wells Fargo Healthcare Conference announcement
• Negative Sentiment: One near-term estimate was reduced. Zacks lowered its Q2 2027 EPS forecast to $0.06 from $0.07, indicating some modest pressure in the intermediate outlook. However, the cut was outweighed by increases to most other quarterly and annual forecasts.

About Glaukos

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.